Neurocrine Data Shows INGREZZA Outperforms AUSTEDO in Real-World Persistence
Event summary
- A real-world claims analysis found INGREZZA (valbenazine) demonstrated higher treatment persistence compared to AUSTEDO XR (deutetrabenazine) among adult TD patients.
- INGREZZA patients showed a 55.6% persistence rate after six months, compared to 48.1% for AUSTEDO XR.
- Switching rates were lower for INGREZZA (7.7%) versus AUSTEDO XR (11.2%).
- The analysis included 2,988 patients, matched using propensity score matching, and utilized IQVIA’s U.S. Longitudinal Access and Adjudication Data (LAAD).
The big picture
This analysis underscores the importance of treatment adherence in managing tardive dyskinesia, a condition affecting an estimated 800,000 adults in the U.S. Neurocrine’s data suggests INGREZZA offers a clinical advantage in terms of patient retention, potentially strengthening its position in a market increasingly focused on long-term efficacy and patient-reported outcomes. The findings also highlight the growing utility of real-world evidence in informing treatment decisions and shaping pharmaceutical marketing strategies.
What we're watching
- Market Adoption
- The impact of this data on physician prescribing habits and INGREZZA’s market share within the TD treatment landscape warrants close monitoring, particularly as AUSTEDO XR’s exclusivity expires.
- Competitive Response
- How AUSTEDO XR’s manufacturer will respond to this data, potentially through marketing campaigns or further clinical studies, will be crucial in maintaining its position.
- Regulatory Scrutiny
- The FDA’s potential review of the methodology and findings of this real-world analysis could influence future claims-based research and marketing practices within the neurology space.
Related topics